Reference range of serum calcitonin levels in humans: Influence of calcitonin assays, sex, age, and cigarette smoking

European Journal of Endocrinology

Volumn 157, Issue 6, 2007, Pages 749-755

  d'Herbomez, Michèle ^a   Caron, Philippe ^b   Bauters, Catherine ^a   Cao, Christine Do ^a   Schlienger, Jean Louis ^c   Sapin, Rémy ^d   Baldet, Line ^e   Carnaille, Bruno ^a   Wémeau, Jean Louis ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b CHU RANGUEIL   (France)

^c HÔPITAL DE HAUTEPIERRE   (France)

^d Institut de Physique Biologique   (France)

^e MONTPELLIER UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN; CALCIUM; GASTRIN; PROCALCITONIN; THYROID PEROXIDASE ANTIBODY; THYROTROPIN; UREA; ANTIBODY; IODIDE PEROXIDASE; PROTEIN PRECURSOR; TUMOR MARKER;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; BODY MASS; CALCITONIN BLOOD LEVEL; CALCIUM BLOOD LEVEL; CIGARETTE SMOKING; CONTROLLED STUDY; FEMALE; GASTRIN BLOOD LEVEL; HUMAN; IMMUNOASSAY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REFERENCE VALUE; THYROID MEDULLARY CARCINOMA; THYROTROPIN BLOOD LEVEL; UREA BLOOD LEVEL; ANALYTICAL EQUIPMENT; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; IMMUNOLOGY; MEDULLARY CARCINOMA; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; SMOKING; THYROID TUMOR;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIBODIES; CALCITONIN; CALCIUM; CARCINOMA, MEDULLARY; FEMALE; GASTRINS; HUMANS; IMMUNOASSAY; IODIDE PEROXIDASE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROTEIN PRECURSORS; REAGENT KITS, DIAGNOSTIC; REFERENCE VALUES; SMOKING; THYROID NEOPLASMS; THYROTROPIN; TUMOR MARKERS, BIOLOGICAL; UREA;

EID: 38349068615     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/EJE-07-0566     Document Type: Article

References (41)

1. Gacel RF, Hoff AO & Cote GJ. Medullary thyroid carcinoma. In The Thyroid Werner and Ingbar's 2004 edn 9 pp 967-988.
2. Henry JF, Denizot A, Puccini M, Gramatica L, Kvachenyuk A, Conte Devolx B & De Micco C. Latent subclinical medullary thyroid carcinoma: diagnosis and treatment. World Journal of Surgery 1998 22 752-756.
3. Pacini F, Fontanelli M, Fugazzola L, Elisei R, Romei C, Di Coscio G, Miccoli P & Pinchera A. Routine measurement of serum calcitonin in nodular thyroid diseases allows the preoperative diagnosis of unsuspected sporadic medullary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 1994 78 826-829.
4. Niccoli P, Wion-Barbot N, Caron F, Henry JF, de Micco C, Saint Andre JP, Bigorgne JC, Modigliani E & Conte-Devolx B. Interest of routine measurement of serum calcitonin: study in a large series of thyroidectomized patients. The French Medullary Study Group. Journal of Clinical Endocrinology and Metabolism 1997 82 338-341.
5. Rieu M, Lame MC, Richard A, Lissak B, Sambort B, Vuong-Ngoc P, Berrod JL & Fombeur JP. Prevalence of sporadic medullary thyroid carcinoma: the importance of routine measurement of serum calcitonin in the diagnostic evaluation of thyroid nodules. Clinical Endocrinology 1995 42 453-460.
6. Vantyghem MC, Pigny P, Leteurtre E, Leclerc L, Banters C, Douillard C, D'Herbomez M, Carnaille B, Proye C, Wemeau JL & Lecomte-Houcke M. Thyroid carcinomas involving follicular and parafollicular C cells: seventeen cases with characterization of RET oncogenic activation. Thyroid 2004 14 842-847.
7. Vierhapper H, Raber W, Bieglmayer C, Kaserer K, Weinhausl A & Niederle B. Routine measurement of plasma calcitonin in nodular thyroid diseases. Journal of Clinical Endocrinology and Metabolism 1997 82 1589-1593.
8. Hahm JR, Lee MS, Min YK, Lee MK, Kim KW, Nam SJ, Yang JH & Chung JH. Routine measurement of serum calcitonin is useful for early detection of medullary thyroid carcinoma in patients with nodular thyroid diseases. Thyroid 2001 11 73-80.
9. Vierhapper H, Niederle B, Bieglmayer C, Kaserer K & Baumgartner-Parzer S. Early diagnosis and curative therapy of medullary thyroid carcinoma by routine measurement of serum calcitonin in patients with thyroid disorders. Thyroid 2005 15 1267-1272.
10. Cohen R, Campos JM, Salaun C, Heshmati HM, Kraimps JL, Proye C, Sarfati E, Henry JF, Niccoli-Sire P & Modighani E. Preoperative calcitonin levels arc predictive of tumor size and postoperative calcitonin normalization in medullary thyroid carcinoma. Groupe d'Etudes des Tumeurs a Calcitonine (GETC). Journal of Clinical Endocrinology and Metabolism 2000 85 919-922.
11. Leboulleux S, Baudin E, Travagli JP & Schlumberger M. Medullary thyroid carcinoma. Clinical Endocrinology 2004 61 299-310 (Review).
12. Scheuba C, Kaserer K, Weinhausl A, Pandev R, Kaider A, Passler C, Prager G, Vierhapper H, Haas OA & Niederle B. Is medullary thyroid cancer predictable? A prospective study of 86 patients with abnormal pentagastrin tests. Surgery 1999 126 1089-1095.
13. Elisei R, Bottici V, Luchetti F, Di Coscio G, Romei C, Grasso L, Miccoli P, Iacconi P, Basolo F, Pinchera A & Pacini F. Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10 864 patients with nodular thyroid disorders. Journal of Clinical Endocrinology and Metabolism 2004 89 163-168.
14. Guyetant S, Wion-Barbot N, Rousselet MC, Franc B, Bigorgne JC & Saint-Andre JF. C-cell hyperplasia associated with chronic lymphocytic thyroiditis: a retrospective quantitative study of 112 cases. Human Pathology 1994 25 514-521.
15. Iacobone M, Niccoli-Sire P, Sebag F, De Micco C & Henry JF. Can sporadic medullary thyroid carcinoma be biochemically predicted? Prospective analysis of 66 operated patients with elevated serum calcitonin levels. World Journal of Surgery 2002 26 886-890.
16. Niccoli P, Conte-Devolx B, Lejeune PJ, Carayon P, Henry JF, Roux F, Wion-Barbot N & Bigorgne JC. Hypercalcitoninemia in conditions other than medullary cancers of the thyroid. Annales d'Endocrinologie 1996 57 15-21.
17. Lissak B, Baudin E, Cohen R, Barbot N, Meyrier A, Niccoli P, Bouyge N & Modigliani E. Pentagastrin testing in patients with renal insufficiency: normal responsivity of mature calcitonin. Thyroid 1998 8 265-268.
18. Niccoli P, Brunet P, Roubicek C, Roux E, Baudin E, Lejeune PJ, Berland Y & Conte-Devolx B. Abnormal calcitonin basal levels and pentagastrin response in patients with chronic renal failure on maintenance hemodialysis. European Journal of Endocrinology 1995 132 75-81.
19. Karanikas G, Moameni A, Poetzi C, Zettinig G, Kaserer K, Bieglmayer C, Niederle B, Dudczak R & Pirich C. Frequency and relevance of elevated calcitonin levels in patients with neoplastic and nonneoplastic thyroid disease and in healthy subjects. Journal of Clinical Endocrinology and Metabolism 2004 89 515-519.
20. Pantazi H & Papapetrou PD. Calcitunin levels are similar in goitrous euthyroid patients with or without thyroid antibodies, as well as in hypothyroid patients. European Journal of Endocrinology 1998 138 530-535.
21. Hadjadj S, Nunez S, Bohme P, Goulet Salmon B, Klein M, Weryha G & Leclere J. False elevated serum level of circulating calcitonin induced by omeprazole. Presse Médicale 1997 26 1859.
22. d'Herbomez M, Leclerc L, Vantyghem MC, Fourrier F, Proye C & Werneau JL. Clinical evaluation of a new sensitive calcitonin assay: study of specificity. Clinica Chimica Acta 2001 311 149-155.
23. Vlaeminck-Guillem V, d'Herbomez M, Pigny P, Fayard A, Banters C, Decoulx M & Wemeau JL. Pseudohypoparathyroidism Ia and hypercalcitoninernia. Journal of Clinical Endocrinology and Metabolism 2001 86 3091-3096.
24. Papapetrou PD, Polymeris A, Karga H & Vaiopoulos G. Heterophilic antibodies causing falsely high serum calcitonin values. Journal of Endocrinological Investigation 2006 29 919-923.
25. Borget I, De Pouvourville G & Schlumberger M. Editorial: calcitonin determination in patients with nodular thyroid disease. Journal of Clinical Endocrinology and Metabolism 2007 92 425-427.
26. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Sherman SI & Tuttle RM. The American Thyroid Association Guidelines Taskforce. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006 16 109-142.
27. Baloch Z, Carayon P, Conte-Devoix B, Demers LM, Feldt-Rasmussen U, Henry JF, LiVosli VA, Niccoli-Sire P, John R, Ruf J, Smyth PF, Spencer CA & Stockigt JR. Guidelines Committee, National Academy of Clinical Biochemistry. Laboratory medicine practice guidelines. Laboratory support for the diagnosis and monitoring of thyroid disease. Thyroid 2003 13 3-126.
28. Verga U, Morpurgo PS, Vaghi I, Radetti G & Beck-Peccoz P. Normal range of calcitonin in children measured by a chemiluminescent two-site immunometric assay. Hormone Research 2006 66 17-20.
29. Basuyau JP, Mallet E, Leroy M & Brunelle P. Reference intervals for serum calcitonin in men, women, and children. Clinical Chemistry 2004 50 1828-1830.
30. Bieglmayer C, Scheuba C, Niederle B, Flores J & Vierhapper H. Screening for medullary thyroid carcinoma: experience with different immunoassays for human calcitonin. Wiener Klinische Wochenschrift 2002 114 267-273.
31. Bieglmayer C, Vierhapper H, Dudczak R & Niederle B. Measurement of calcitonin by immunoassay analyzers. Clinical Chemistry and Laboratory Medicine 2007 45 662-666.
32. Costante G, Meringolo D, Durante C, Bianchi D, Noccra M, Tumino S, Crocetti U, Attard M, Maranghi M, Torlontano M & Filetti S. Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules. Journal of Clinical Endocrinology and Metabolism 2007 92 450-455.
33. Guyetant S, Rousselet MC, Durigon M, Chappard D, Franc B, Guerin O & Saint-Andre JP. Sex-related C cell hyperplasia in the normal human thyroid: a quantitative autopsy study. Journal of Clinical Endocrinology and Metabolism 1997 82 42-47.
34. Engetbach M, Gorges R, Forst T, Pfutzner A, Dawood R, Heerdt S, Knot T, Bockisch A & Beyer J. Improved diagnostic methods in the follow-up of medullary thyroid carcinoma by highly specific calcitonin measurements. Journal of Clinical Endocrinology and Metabolism 2000 85 1890-1894.
35. Schlienger JL, Grunenberger F, Vinzio S & Goichot B. Smoking and the thyroid. Annales d'Endocrinologie 2003 64 309-315.
36. Vestergaard P. Smoking and thyroid disorders - a meta-analysis. European Journal of Endocrinology 2002 146 153-161.
37. Prummel ME Strieder T & Wiersinga WM. The environment and autoimmune thyroid diseases. European Journal of Endocrinology 2004 150 605-618 (Review).
38. Kapoor D & Jones TH. Smoking and hormones in health and endocrine disorders. European Journal of Endocrinology 2005 152 491-499 (Review).
39. Tabassian AR, Nylen ES, Giron AE, Snider RH, Cassidy MM & Becker KL. Evidence for cigarette smoke-induced calcitonin secretion from lungs of man and hamster. Life Sciences 1988 42 2323-2329.
40. Tabassian AR, Snider RH, Jr, Nylen ES, Cassidy M & Becker KL. Heterogeneity studies of hamster calcitonin following acute exposure to cigarette smoke: evidence for monomeric secretion. Anatomical Record 1993 236 253-256.
41. Vantyghem MC, Danel T, Marcelli-Tourvielle S, Moriau J, Leclerc L, Cardot-Bauters C, Do Cao C, Carnaille B, Wémeau JL & d'Herbomez M. Calcitonin levels do not decrease with weaning in chronic alcoholism. Thyroid 2007 17 213-217.